Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.

Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, Huang Y, Geradts J, Jiang P, Fei T, Chi D, Zang C, Liao Q, Rennhack J, Andrechek E, Li N, Detre S, Dowsett M, Jeselsohn RM, Liu XS, Brown M.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7869-7878. doi: 10.1073/pnas.1722617115. Epub 2018 Jul 9.


Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice.

Zhang D, Rennhack J, Andrechek ER, Rockwell CE, Liby KT.

Antioxid Redox Signal. 2018 Dec 1;29(16):1535-1552. doi: 10.1089/ars.2017.7201. Epub 2018 Apr 16.


Transcription factor compensation during mammary gland development in E2F knockout mice.

To B, Andrechek ER.

PLoS One. 2018 Apr 4;13(4):e0194937. doi: 10.1371/journal.pone.0194937. eCollection 2018.


Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.

Annis MG, Ouellet V, Rennhack JP, L'Esperance S, Rancourt C, Mes-Masson AM, Andrechek ER, Siegel PM.

Breast Cancer Res. 2018 Jan 30;20(1):9. doi: 10.1186/s13058-018-0936-8.


Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers.

Hollern DP, Swiatnicki MR, Andrechek ER.

PLoS Genet. 2018 Jan 18;14(1):e1007135. doi: 10.1371/journal.pgen.1007135. eCollection 2018 Jan.


Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial.

Reaz S, Tamkus D, Andrechek ER.

J Mol Med (Berl). 2018 Feb;96(2):111-117. doi: 10.1007/s00109-017-1620-7. Epub 2018 Jan 8. Review.


Triple-negative breast cancer and the potential for targeted therapy.

Jhan JR, Andrechek ER.

Pharmacogenomics. 2017 Nov;18(17):1595-1609. doi: 10.2217/pgs-2017-0117. Epub 2017 Nov 2. Review.


Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.

Jhan JR, Andrechek ER.

Oncogene. 2017 Jun 22;36(25):3553-3561. doi: 10.1038/onc.2016.503. Epub 2017 Jan 30.


Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer.

Rennhack J, To B, Wermuth H, Andrechek ER.

J Mammary Gland Biol Neoplasia. 2017 Mar;22(1):71-84. doi: 10.1007/s10911-017-9374-y. Epub 2017 Jan 26.


LPA receptor activity is basal specific and coincident with early pregnancy and involution during mammary gland postnatal development.

Acosta D, Bagchi S, Broin PÓ, Hollern D, Racedo SE, Morrow B, Sellers RS, Greally JM, Golden A, Andrechek E, Wood T, Montagna C.

Sci Rep. 2016 Nov 3;6:35810. doi: 10.1038/srep35810.


Stat3 accelerates Myc induced tumor formation while reducing growth rate in a mouse model of breast cancer.

Jhan JR, Andrechek ER.

Oncotarget. 2016 Oct 4;7(40):65797-65807. doi: 10.18632/oncotarget.11667.


Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.

Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM.

Cancer Immunol Res. 2016 Jul;4(7):600-10. doi: 10.1158/2326-6066.CIR-15-0149. Epub 2016 Apr 28.


The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.

Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, Rennhack JP, Andrechek ER, Ozcelik J, Hallett M, Mills GB, Cardiff RD, Gray JW, Griffith OL, Muller WJ.

Oncogene. 2016 Nov 24;35(47):6053-6064. doi: 10.1038/onc.2016.129. Epub 2016 May 9.


Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion.

Cyr-Depauw C, Northey JJ, Tabariès S, Annis MG, Dong Z, Cory S, Hallett M, Rennhack JP, Andrechek ER, Siegel PM.

Mol Cell Biol. 2016 May 2;36(10):1509-25. doi: 10.1128/MCB.00600-15. Print 2016 May 15.


Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients.

Rennhack J, Andrechek E.

Oncoscience. 2015 Nov 10;2(10):867-71. eCollection 2015.


Increased metastasis with loss of E2F2 in Myc-driven tumors.

Yuwanita I, Barnes D, Monterey MD, O'Reilly S, Andrechek ER.

Oncotarget. 2015 Nov 10;6(35):38210-24. doi: 10.18632/oncotarget.5690.


Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation.

Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, Ogrodzinski M, Hecht V, Xu K, Acevedo PN, Hollern DP, Bellinger G, Dayton TL, Christen S, Elia I, Dinh AT, Stephanopoulos G, Manalis SR, Yaffe MB, Andrechek ER, Fendt SM, Vander Heiden MG.

Mol Cell. 2015 Jan 8;57(1):95-107. doi: 10.1016/j.molcel.2014.10.027. Epub 2014 Dec 4.


The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.

Hollern DP, Honeysett J, Cardiff RD, Andrechek ER.

Mol Cell Biol. 2014 Sep;34(17):3229-43. doi: 10.1128/MCB.00737-14. Epub 2014 Jun 16.


Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression.

Chen F, Li A, Gao S, Hollern D, Williams M, Liu F, VanSickle EA, Andrechek E, Zhang C, Yang C, Luo R, Xiao H.

Cell Death Dis. 2014 May 22;5:e1242. doi: 10.1038/cddis.2014.224.


HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors.

Andrechek ER.

Oncogene. 2015 Jan 8;34(2):217-25. doi: 10.1038/onc.2013.540. Epub 2013 Dec 23.


NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors.

Zhou X, Hollern D, Liao J, Andrechek E, Wang H.

Cell Death Dis. 2013 Mar 28;4:e560. doi: 10.1038/cddis.2013.82.


A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer.

Hollern DP, Yuwanita I, Andrechek ER.

Oncogene. 2013 Mar 7;32(10):1296-304. doi: 10.1038/onc.2012.142. Epub 2012 Apr 23.


Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.

Leung JY, Andrechek ER, Cardiff RD, Nevins JR.

Oncogene. 2012 May 17;31(20):2545-54. doi: 10.1038/onc.2011.433. Epub 2011 Sep 26.


Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors.

Fujiwara K, Yuwanita I, Hollern DP, Andrechek ER.

Cancer Res. 2011 Mar 1;71(5):1924-32. doi: 10.1158/0008-5472.CAN-10-2386. Epub 2011 Jan 18.


Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies.

Andrechek ER, Nevins JR.

J Mol Med (Berl). 2010 Nov;88(11):1095-100. doi: 10.1007/s00109-010-0644-z. Epub 2010 Jun 24. Review.


Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.

Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, Nevins JR.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16387-92. doi: 10.1073/pnas.0901250106. Epub 2009 Sep 4.


A role for E2F activities in determining the fate of Myc-induced lymphomagenesis.

Rempel RE, Mori S, Gasparetto M, Glozak MA, Andrechek ER, Adler SB, Laakso NM, Lagoo AS, Storms R, Smith C, Nevins JR.

PLoS Genet. 2009 Sep;5(9):e1000640. doi: 10.1371/journal.pgen.1000640. Epub 2009 Sep 11.


Utilization of genomic signatures to identify phenotype-specific drugs.

Mori S, Chang JT, Andrechek ER, Potti A, Nevins JR.

PLoS One. 2009 Aug 28;4(8):e6772. doi: 10.1371/journal.pone.0006772.


Anchorage-independent cell growth signature identifies tumors with metastatic potential.

Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR.

Oncogene. 2009 Aug 6;28(31):2796-805. doi: 10.1038/onc.2009.139. Epub 2009 Jun 1.


Patterns of cell signaling pathway activation that characterize mammary development.

Andrechek ER, Mori S, Rempel RE, Chang JT, Nevins JR.

Development. 2008 Aug;135(14):2403-13. doi: 10.1242/dev.019018. Epub 2008 Jun 11.


Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.

Giangrande PH, Zhang J, Tanner A, Eckhart AD, Rempel RE, Andrechek ER, Layzer JM, Keys JR, Hagen PO, Nevins JR, Koch WJ, Sullenger BA.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):12988-93. Epub 2007 Jul 25.


Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH.

Nat Biotechnol. 2006 Aug;24(8):1005-15. Epub 2006 Jun 25.


Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth.

Andrechek ER, White D, Muller WJ.

Oncogene. 2005 Jan 27;24(5):932-7.


Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.

Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, Carothers Carraway CA, Muller WJ, Carraway KL.

J Cell Physiol. 2005 Apr;203(1):44-53.


Developmental timing of activated erbB2 expression plays a critical role in the induction of mammary tumors.

Andrechek ER, Muller WJ.

Cell Cycle. 2004 Sep;3(9):1111-3. Epub 2004 Sep 1. Review.


Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis.

Andrechek ER, Hardy WR, Laing MA, Muller WJ.

Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4984-9. Epub 2004 Mar 29.


Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers.

Andrechek ER, Laing MA, Girgis-Gabardo AA, Siegel PM, Cardiff RD, Muller WJ.

Cancer Res. 2003 Aug 15;63(16):4920-6.


ErbB2 is required for muscle spindle and myoblast cell survival.

Andrechek ER, Hardy WR, Girgis-Gabardo AA, Perry RL, Butler R, Graham FL, Kahn RC, Rudnicki MA, Muller WJ.

Mol Cell Biol. 2002 Jul;22(13):4714-22.


Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis.

Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3444-9.


Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein.

Rauh MJ, Blackmore V, Andrechek ER, Tortorice CG, Daly R, Lai VK, Pawson T, Cardiff RD, Siegel PM, Muller WJ.

Mol Cell Biol. 1999 Dec;19(12):8169-79.

Supplemental Content

Loading ...
Support Center